Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Antiemetic 5-HT3 antagonist launched in Japan

Sep. 20, 1996

Roquinimex in MS

Sep. 20, 1996

Idebenone evaluated in Huntington's disease

Sep. 20, 1996

Generic clonazepam approved

Sep. 20, 1996

Forest prepares NDA submission for antidepressant

Sep. 20, 1996

Hoechst Marion Roussel reports new antidepressants

Sep. 20, 1996

Fluphenazine ANDA approval

Sep. 20, 1996

New dopamine D4 receptor antagonists from Taisho and Nihon Nohyaku

Sep. 20, 1996

Anxiolytic/antidepressant approved in Japan

Sep. 20, 1996

Mitochondrial benzodiazepine receptor (MBR) ligands as potential anxiolytics

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...